Strategic Lowering of LDL-cholesterol Post Ischemic Stroke: Identifying Optimal Targets, Timing, and Therapeutic Approaches

Abstract

Stroke remains a leading cause of morbidity and mortality worldwide, with ischemic stroke dominating the landscape. Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a critical modifiable risk factor in both primary and secondary prevention of stroke. While statins have established their role in stroke prevention, questions remain regarding optimal treatment strategies for specific patient groups, the role of non-statin therapies, and lipid level targets for maximal benefit. Emerging evidence underscores the potential of novel lipid-lowering agents, namely, PCSK9 injectable therapies targeting PCSK9, bempedoic acid, and icosapent ethyl, to complement statins in specific patient groups, including those with statin intolerance, those needing further LDL reduction, and those at high residual risk because of high triglycerides. Furthermore, the variability in stroke subtypes and patient comorbidities highlights the need for individualized, evidence-based approaches to lipid management. This narrative review provides a comprehensive overview of available lipid-lowering therapies for post-stroke patients, proposing practical algorithms for “who” to treat, “how” to treat them, and “how much” LDL-C reduction is needed. We aim to bridge gaps between clinical evidence and practice, focusing on individualized approaches to improve outcomes in this high-risk population.

Keywords

ischemic stroke - lipid-lowering therapy - prevention - treatment targets

Publication History

Received: 18 February 2025

Accepted: 01 August 2025

Accepted Manuscript online:
04 August 2025

Article published online:
19 August 2025

• References

• 1 Klijn CJ, Hankey GJ. American Stroke Association and European Stroke Initiative. Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative. Lancet Neurol 2003; 2 (11) 698-701
• 2 Hackam DG, Hegele RA. Cholesterol lowering and prevention of stroke. Stroke 2019; 50 (02) 537-541
• 3 Navar AM, Kolkailah AA, Gupta A. et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322 153 patients. Circ Cardiovasc Qual Outcomes 2023; 16 (08) 533-543
• 4 Chang Y, Eom S, Kim M, Song TJ. Medical management of dyslipidemia for secondary stroke prevention: narrative review. Medicina (Kaunas) 2023; 59 (04) 776
• 5 Dawson J, Béjot Y, Christensen LM. et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J 2022; 7 (03) I-II
• 6 Borén J, Chapman MJ, Krauss RM. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41 (24) 2313-2330
• 7 Katsiki N, Filippatos T, Vlachopoulos C. et al. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023. Atheroscler Plus 2024; 55: 74-92
• 8 Mach F, Baigent C, Catapano AL. et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41 (01) 111-188
• 9 Sagris D, Ntaios G, Georgiopoulos G. et al. Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: a clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. Int J Stroke 2021; 16 (06) 738-750
• 10 Duell PB. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk. J Am Coll Cardiol 2023; 81 (02) 153-155
• 11 Kumar P, Swarnkar P, Misra S, Nath M. Lipoprotein (a) level as a risk factor for stroke and its subtype: a systematic review and meta-analysis. Sci Rep 2021; 11 (01) 15660
• 12 Konishi M, Iso H, Komachi Y. et al. Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke 1993; 24 (07) 954-964
• 13 Wannamethee SG, Shaper AG, Ebrahim S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 2000; 31 (08) 1882-1888
• 14 Imamura T, Doi Y, Arima H. et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2009; 40 (02) 382-388
• 15 Glasser SP, Mosher A, Howard G, Banach M. What is the association of lipid levels and incident stroke?. Int J Cardiol 2016; 220: 890-894
• 16 Milionis H, Ntaios G, Korompoki E, Vemmos K, Michel P. Statin-based therapy for primary and secondary prevention of ischemic stroke: a meta-analysis and critical overview. Int J Stroke 2020; 15 (04) 377-384
• 17 Prats-Sanchez L, Werring DJ, Marti-Fabregas J. Author response: statin therapy for secondary prevention in ischemic stroke patients with cerebral microbleeds. Neurology 2024; 103 (10) e209595
• 18 Hitman GA, Colhoun H, Newman C. et al; CARDS Investigators. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med 2007; 24 (12) 1313-1321
• 19 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326) 7-22
• 20 Kitagawa K, Hosomi N, Nagai Y. et al; J-STARS collaborators. Cumulative effects of LDL cholesterol and CRP levels on recurrent stroke and TIA. J Atheroscler Thromb 2019; 26 (05) 432-441
• 21 Pan Y, Wangqin R, Li H. et al. LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA. Stroke Vasc Neurol 2022; 7 (04) 276-284
• 22 Ntaios G, Milionis H. Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke. Int J Stroke 2019; 14 (05) 476-482
• 23 Byrne RA, Rossello X, Coughlan JJ. et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44 (38) 3720-3826
• 24 Powers WJ, Rabinstein AA, Ackerson T. et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019; 50 (12) e344-e418
• 25 Blanco M, Nombela F, Castellanos M. et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69 (09) 904-910
• 26 Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30 (09) 1969-1973
• 27 Gao Y, Jiang L, Pan Y. et al; INSPIRES Investigators. Immediate- or delayed-intensive statin in acute cerebral ischemia: the INSPIRES randomized clinical trial. JAMA Neurol 2024; 81 (07) 741-751
• 28 Yoshimura S, Uchida K, Daimon T, Takashima R, Kimura K, Morimoto T. ASSORT Trial Investigator. Randomized controlled trial of early versus delayed statin therapy in patients with acute ischemic stroke: ASSORT trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke 2017; 48 (11) 3057-3063
• 29 Montaner J, Bustamante A, García-Matas S. et al; STARS Investigators. Combination of thrombolysis and statins in acute stroke is safe: results of the STARS randomized trial (Stroke Treatment With Acute Reperfusion and Simvastatin). Stroke 2016; 47 (11) 2870-2873
• 30 Heo JH, Song D, Nam HS. et al; EUREKA Investigators. Effect and safety of rosuvastatin in acute ischemic stroke. J Stroke 2016; 18 (01) 87-95
• 31 Choi SE, Bucci T, Huang JY. et al. Early statin use is associated with improved survival and cardiovascular outcomes in patients with atrial fibrillation and recent ischaemic stroke: a propensity-matched analysis of a global federated health database. Eur Stroke J 2025; 10 (01) 116-127
• 32 Moonis M, Kumar R, Henninger N, Kane K, Fisher M. Pre and post-stroke use of statins improves stroke outcome. Indian J Community Med 2014; 39 (04) 214-217
• 33 Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005; 36 (06) 1298-1300
• 34 Lee KP, Huang HC, Tsai JY, Hsu LC. Statin treatment in stroke patient with low-density lipoprotein cholesterol levels below 70 mg/dL. J Stroke Cerebrovasc Dis 2024; 33 (05) 107645
• 35 Milionis HJ, Giannopoulos S, Kosmidou M. et al. Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology 2009; 72 (21) 1816-1822
• 36 Amarenco P, Kim JS, Labreuche J. et al; Treat Stroke to Target Investigators. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020; 382 (01) 9
• 37 Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18 (11) 1519-1530
• 38 Nakamura H, Arakawa K, Itakura H. et al; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368 (9542) 1155-1163
• 39 Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010; 121 (01) 143-150
• 40 Hosomi N, Nagai Y, Kohriyama T. et al; J-STARS Collaborators. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study. EBioMedicine 2015; 2 (09) 1071-1078
• 41 Amarenco P, Bogousslavsky J, Callahan III A. et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355 (06) 549-559
• 42 Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363 (9411) 757-767
• 43 Bohula EA, Wiviott SD, Giugliano RP. et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2017; 136 (25) 2440-2450
• 44 Plehn JF, Davis BR, Sacks FM. et al; The Care Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999; 99 (02) 216-223
• 45 White HD, Simes RJ, Anderson NE. et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343 (05) 317-326
• 46 Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-427
• 47 Cannon CP, Blazing MA, Giugliano RP. et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372 (25) 2387-2397
• 48 Xia XD, Peng ZS, Gu HM, Wang M, Wang GQ, Zhang DW. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front Cardiovasc Med 2021; 8: 764038
• 49 Sabatine MS, Giugliano RP, Keech AC. et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722
• 50 Giugliano RP, Pedersen TR, Park J-G. et al; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 2017; 390 (10106): 1962-1971
• 51 Giugliano RP, Pedersen TR, Saver JL. et al; FOURIER Investigators. Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke 2020; 51 (05) 1546-1554
• 52 Schwartz GG, Steg PG, Szarek M. et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379 (22) 2097-2107
• 53 Jukema JW, Zijlstra LE, Bhatt DL. et al; ODYSSEY OUTCOMES Investigators. Effect of alirocumab on stroke in ODYSSEY OUTCOMES. Circulation 2019; 140 (25) 2054-2062
• 54 Ray KK, Raal FJ, Kallend DG. et al; ORION Phase III investigators. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J 2023; 44 (02) 129-138
• 55 Kosmas CE, Muñoz Estrella A, Skavdis A, Peña Genao E, Martinez I, Guzman E. Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential. Ther Clin Risk Manag 2020; 16: 1031-1037
• 56 Marrs JC, Anderson SL. Inclisiran for the treatment of hypercholesterolaemia. Drugs Context 2024; 13: 2023-2013
• 57 Laufs U, Banach M, Mancini GBJ. et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 2019; 8 (07) e011662
• 58 Nissen SE, Lincoff AM, Brennan D. et al; CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 388 (15) 1353-1364
• 59 Mutschlechner D, Tscharre M, Huber K, Gremmel T. Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2023; 9 (06) 583-591
• 60 Balling M, Afzal S, Davey Smith G. et al. Elevated LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 2023; 81 (02) 136-152
• 61 Bhatt DL, Steg PG, Miller M. et al; REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol 2019; 73 (22) 2791-2802
• 62 Kleindorfer DO, Towfighi A, Chaturvedi S. et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52 (07) e364-e467
• 63 Karwatowska-Prokopczuk E, Lesogor A, Yan JH. et al. Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects. J Clin Lipidol 2023; 17 (01) 181-188
• 64 O'Donoghue ML, Rosenson RS, Gencer B. et al; OCEAN(a)-DOSE Trial Investigators. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022; 387 (20) 1855-1864
• 65 Nissen SE, Linnebjerg H, Shen X. et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA 2023; 330 (21) 2075-2083
• 66 Nissen SE, Wang Q, Nicholls SJ. et al. Zerlasiran—a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA 2024; 332 (23) 1992-2002
• 67 Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008; 39 (02) 497-502
• 68 Karagiannis AD, Mehta A, Dhindsa DS. et al. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J 2021; 42 (22) 2154-2169
• 69 Goldstein LB, Amarenco P, Szarek M. et al; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70 (24 Pt 2): 2364-2370
• 70 Huisa BN, Stemer AB, Zivin JA. Atorvastatin in stroke: a review of SPARCL and subgroup analysis. Vasc Health Risk Manag 2010; 6: 229-236
• 71 Spence JD. Intracerebral hemorrhage in SPARCL. J Am Coll Cardiol 2020; 76 (07) 885-886
• 72 Masson W, Lobo M, Siniawski D, Masson G, Lavalle-Cobo A, Molinero G. LDL-C levels below 55 mg/dl and risk of hemorrhagic stroke: a meta-analysis. J Stroke Cerebrovasc Dis 2021; 30 (04) 105655
• 73 Goldstein LB, Toth PP, Dearborn-Tomazos JL. et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular and Stroke Nursing, Council on Peripheral Vascular Disease, and Stroke Council. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2023; 43 (10) e404-e442
• 74 Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46 (08) 1411-1416
• 75 Robinson JG, Rosenson RS, Farnier M. et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol 2017; 69 (05) 471-482
• 76 Amarenco P, Kim JS, Labreuche J. et al; Treat Stroke to Target Investigators. Benefit of targeting a LDL (low-density lipoprotein) cholesterol <70 mg/dL during 5 years after ischemic stroke. Stroke 2020; 51 (04) 1231-1239
• 77 Giugliano RP, Wiviott SD, Blazing MA. et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol 2017; 2 (05) 547-555
• 78 Gaba P, O'Donoghue ML, Park J-G. et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation 2023; 147 (16) 1192-1203
• 79 Marte Chacra AP, Saldanha ALR, Pantoja Margeotto AP. et al. Confluence of Mendelian randomization with clinical trials as to very low levels of LDL cholesterol. Clin Med Health Res J 2024; 4 (01) 756-760
• 80 Nicholls SJ, Puri R, Anderson T. et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 2016; 316 (22) 2373-2384
• 81 Giugliano RP, Mach F, Zavitz K. et al; EBBINGHAUS Investigators. Cognitive function in a randomized trial of evolocumab. N Engl J Med 2017; 377 (07) 633-643
• 82 Taylor BA, Dager AD, Panza GA. et al. The effect of high-dose atorvastatin on neural activity and cognitive function. Am Heart J 2018; 197: 166-174
• 83 Shimazaki Y, Kishimoto K, Ishikawa J, Iwakiri R, Araki A, Imai S. Association between cognitive impairment severity and polypharmacy in older patients with atrial fibrillation: a retrospective study using inpatient data from a specialised geriatric hospital. Geriatrics (Basel) 2024; 9 (01) 15
• 84 Mahavadia M, Agrawal A. Medication adherence among post-stroke elderly patients: a cross-sectional study. Cureus 2025; 17 (04) e83052
• 85 Nissen SE, Stroes E, Dent-Acosta RE. et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 2016; 315 (15) 1580-1590
• 86 Wright RS, Kallend D, Raal FJ. et al. Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11). Eur Heart J 2020; 41 (Suppl. 02) ehaa946.3009
• 87 Moriarty PM, Thompson PD, Cannon CP. et al. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. J Clin Lipidol 2020; 14 (01) 88-97.e2
• 88 Ballantyne CM, Banach M, Mancini GBJ. et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 2018; 277: 195-203
• 89 Jia X, Virani SS. CLEAR Serenity trial: more clarity for the future of bempedoic acid in patients unable to take statins?. J Am Heart Assoc 2019; 8 (07) e012352
• 90 Pogran E, Burger AL, Zweiker D. et al. Lipid-lowering therapy after acute coronary syndrome. J Clin Med 2024; 13 (07) 2043
• 91 Abduljabbar MH. PCSK9 inhibitors: focus on evolocumab and its impact on atherosclerosis progression. Pharmaceuticals (Basel) 2024; 17 (12) 1581
• 92 Kung N, Brorson JR. Novel Lipid-Lowering Agents and Stroke Prevention: New Tools, New Targets. Practical Neurology; 2023 . Accessed at: https://practicalneurology.com/articles/2023-dec/novel-lipid-lowering-agents-and-stroke-preventionbrnew-tools-new-targets